Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved]
Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked clinically by fatigable muscle weakness and serologically by the presence of autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LPR4). Over the past few...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-10-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-1727/v1 |
| _version_ | 1819173170661294080 |
|---|---|
| author | Allison Jordan Miriam Freimer |
| author_facet | Allison Jordan Miriam Freimer |
| author_sort | Allison Jordan |
| collection | DOAJ |
| description | Autoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked clinically by fatigable muscle weakness and serologically by the presence of autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LPR4). Over the past few decades, the mortality of patients with MG has seen a dramatic decline secondary to evolving interventions in critical care and medical management. In the past 2 to 3 years, there have been several changes in standard of care for the treatment of MG. These changes include confirmation of the benefit of thymectomy versus medical management alone in AChR patients and a new US Food and Drug Administration-approved medication for refractory MG. There are also several exciting new prospective drugs in the pipeline, which are in different stages of clinical trial testing. |
| first_indexed | 2024-12-22T20:18:49Z |
| format | Article |
| id | doaj.art-7b4e6365cf754ab8a91dd0de5e85999c |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-22T20:18:49Z |
| publishDate | 2018-10-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-7b4e6365cf754ab8a91dd0de5e85999c2022-12-21T18:13:55ZengF1000 Research LtdF1000Research2046-14022018-10-01710.12688/f1000research.15973.117445Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved]Allison Jordan0Miriam Freimer1Department of Neurology, The Ohio State Wexner Medical Center, Columbus, Ohio, USADepartment of Neurology, The Ohio State Wexner Medical Center, Columbus, Ohio, USAAutoimmune myasthenia gravis (MG) is a neuromuscular junction disorder marked clinically by fatigable muscle weakness and serologically by the presence of autoantibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), or lipoprotein-related protein 4 (LPR4). Over the past few decades, the mortality of patients with MG has seen a dramatic decline secondary to evolving interventions in critical care and medical management. In the past 2 to 3 years, there have been several changes in standard of care for the treatment of MG. These changes include confirmation of the benefit of thymectomy versus medical management alone in AChR patients and a new US Food and Drug Administration-approved medication for refractory MG. There are also several exciting new prospective drugs in the pipeline, which are in different stages of clinical trial testing.https://f1000research.com/articles/7-1727/v1 |
| spellingShingle | Allison Jordan Miriam Freimer Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] F1000Research |
| title | Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] |
| title_full | Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] |
| title_fullStr | Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] |
| title_full_unstemmed | Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] |
| title_short | Recent advances in understanding and managing myasthenia gravis [version 1; referees: 3 approved] |
| title_sort | recent advances in understanding and managing myasthenia gravis version 1 referees 3 approved |
| url | https://f1000research.com/articles/7-1727/v1 |
| work_keys_str_mv | AT allisonjordan recentadvancesinunderstandingandmanagingmyastheniagravisversion1referees3approved AT miriamfreimer recentadvancesinunderstandingandmanagingmyastheniagravisversion1referees3approved |